FOXO Technologies Inc.
Moat Score — FOXO Technologies Inc.
Total Moat Score
2 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 1 / 5 | FOXO's original epigenetic biomarker IP, the basis of its 2022 SPAC listing, has been fully impaired on the balance sheet and the company says it has not secured capital to commercialize it, while its remaining economic value is capped by a license agreement limiting royalties to a 3 percent rate up to $1.3 million; the acquired Healthcare and Vector BioSource assets carry no meaningful proprietary IP of their own. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | FOXO shows no evidence of a cost advantage in any of its three lines -- rural hospital and behavioral-health operations in Tennessee face standard Medicare/Medicaid reimbursement economics, Vector BioSource competes in a described-as-competitive biospecimen sourcing market, and the parent company itself relies on high-cost short-term and related-party debt to fund operations, the opposite of a low-cost structural position. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | A company with a $25.5 million working capital deficit (widening to roughly $35.9 million by mid-2026) and debt obligations already in default has no demonstrated ability to set favorable pricing; its Healthcare segment is largely a price-taker on government reimbursement rates, and its own 10-K cites going-concern doubt rather than any pricing leverage. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | None of FOXO's three businesses -- a rural hospital, a biospecimen sourcing operation, or an unfunded epigenetics R&D unit -- exhibits any network effect where additional users or customers increase the platform's value to others. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Vector BioSource's biotech and pharma research customers may have some minor relationship or sample-sourcing continuity switching costs, but there is no evidence in the filings of meaningful lock-in anywhere in the business, and Healthcare patients in a Tennessee market can generally seek care from other regional providers. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | FOXO is a sub-scale micro-cap with roughly 192 employees across three disparate businesses, a single 25-bed hospital, and a recently acquired biospecimen unit -- there is no evidence of scale sufficient to deter competitors, and the company's own going-concern disclosures and repeated reverse stock splits (most recently 1-for-3,000 in June 2026) reflect financial distress rather than efficient scale. |